全球蛋白质工程市场规模、份额、趋势和成长分析报告（2026-2034年）

蛋白质工程市场预计将从 2025 年的 40.4 亿美元成长到 2034 年的 126 亿美元，2026 年至 2034 年的复合年增长率为 13.47%。

受生物技术、药物研发和合成生物学领域的进步所推动，全球蛋白质工程市场正经历强劲成长。对标靶治疗（包括单株抗体和酵素製剂）的需求不断增长，正在加速市场扩张。製药和生物製药公司正大力投资蛋白质修饰技术，以提高其疗法的疗效、稳定性和特异性。基因组学和蛋白​​质组学领域的研究活动活性化，也为全球市场的持续成长做出了贡献。

主要驱动因素包括癌症、糖尿病和自体免疫疾病等慢性病的日益普遍，这些疾病需要高度特异性的生物疗法。 CRISPR、电脑辅助蛋白质设计和定向进化等技术创新正在提高蛋白质工程的效率。此外，政府和私人机构对生命科学研究投入的增加也促进了市场发展。学术机构和生技公司之间合作的不断深化也增强了创新管道。

展望未来，个人化医疗的发展趋势和人工智慧驱动的蛋白质建模技术的进步有望推动市场成长。工业酵素、农业和环境生物技术领域的新应用将丰富收入来源。随着生物製药继续主导药物开发平臺，蛋白质工程技术的重要性将不减。自动化技术和高通量筛检方法的整合有望进一步加速全球创新和商业性化应用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球蛋白质工程市场：依最终用户划分

• 市场分析、洞察与预测
• 製药和生物技术公司
• 学术研究机构
• 受託研究机构

第五章 全球蛋白质工程市场：依产品划分

• 市场分析、洞察与预测
• 装置
• 消耗品
• 软体

第六章 全球蛋白质工程市场：依技术类型划分

• 市场分析、洞察与预测
• 理性诱变或特异性诱变
• 非理性或随机诱变

第七章 全球蛋白质工程市场：依蛋白质类型划分

• 市场分析、洞察与预测
• 单株抗体
• 胰岛素
• 促红血球生成素
• 干扰素
• 其他的

第八章 全球蛋白质工程市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Takara Holdings Inc
  • Amgen Inc
  • Promega Corporation
  • New England Biolabs Inc
  • Danaher Corporation
  • Bio-Rad Laboratories Inc
  • Creative Biolabs Limited
  • Thermo Fisher Scientific Inc
  • Jena Bioscience GmbH
  • Agilent Technologies Inc

The Protein Engineering Market size is expected to reach USD 12.60 Billion in 2034 from USD 4.04 Billion (2025) growing at a CAGR of 13.47% during 2026-2034.

The Global Protein Engineering Market is witnessing robust growth driven by advancements in biotechnology, drug discovery, and synthetic biology. The increasing demand for targeted therapeutics, including monoclonal antibodies and enzyme-based drugs, is accelerating market expansion. Pharmaceutical and biopharmaceutical companies are investing heavily in protein modification technologies to improve efficacy, stability, and specificity of treatments. Rising research activities in genomics and proteomics further contribute to sustained market growth worldwide.

Key drivers include the growing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which require highly specific biologic therapies. Technological innovations like CRISPR, computational protein design, and directed evolution are enhancing protein engineering efficiency. Additionally, increased funding from governments and private organizations for life sciences research supports market development. Expanding collaborations between academic institutions and biotech firms also strengthen innovation pipelines.

In the future, the market is expected to benefit from personalized medicine trends and advancements in artificial intelligence-driven protein modeling. Emerging applications in industrial enzymes, agriculture, and environmental biotechnology will diversify revenue streams. As biologics continue to dominate the pharmaceutical pipeline, protein engineering technologies will remain critical. The integration of automation and high-throughput screening methods is likely to further accelerate innovation and commercial adoption globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By End User

• Pharmaceutical And Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations

By Product

• Instruments
• Consumables
• Software

By Technology Type

• Rational or Site Directed Mutagenesis
• Irrational or Random Mutagenesis

By Protein Type

• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Interferon
• Others

COMPANIES PROFILED

• Takara Holdings Inc, Amgen Inc, Promega Corporation, New England Biolabs Inc, Danaher Corporation, BioRad Laboratories Inc, Creative Biolabs Limited, Thermo Fisher Scientific Inc, Jena Bioscience GmbH, Agilent Technologies Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROTEIN ENGINEERING MARKET: BY END USER 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast End User
• 4.2. Pharmaceutical And Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROTEIN ENGINEERING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROTEIN ENGINEERING MARKET: BY TECHNOLOGY TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology Type
• 6.2. Rational or Site Directed Mutagenesis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Irrational or Random Mutagenesis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROTEIN ENGINEERING MARKET: BY PROTEIN TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Protein Type
• 7.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Erythropoietin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Interferon Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PROTEIN ENGINEERING MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By End User
  • 8.2.2 By Product
  • 8.2.3 By Technology Type
  • 8.2.4 By Protein Type
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By End User
  • 8.3.2 By Product
  • 8.3.3 By Technology Type
  • 8.3.4 By Protein Type
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By End User
  • 8.4.2 By Product
  • 8.4.3 By Technology Type
  • 8.4.4 By Protein Type
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By End User
  • 8.5.2 By Product
  • 8.5.3 By Technology Type
  • 8.5.4 By Protein Type
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By End User
  • 8.6.2 By Product
  • 8.6.3 By Technology Type
  • 8.6.4 By Protein Type
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PROTEIN ENGINEERING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Takara Holdings Inc
  • 10.2.2 Amgen Inc
  • 10.2.3 Promega Corporation
  • 10.2.4 New England Biolabs Inc
  • 10.2.5 Danaher Corporation
  • 10.2.6 Bio-Rad Laboratories Inc
  • 10.2.7 Creative Biolabs Limited
  • 10.2.8 Thermo Fisher Scientific Inc
  • 10.2.9 Jena Bioscience GmbH
  • 10.2.10 Agilent Technologies Inc